Form 4: Aprea Therapeutics Director Receives Equity Grant

Director Rifat Pamukcu was granted 3,135 restricted stock units and 12,555 stock options as part of board compensation.

Summary

• Director Rifat Pamukcu acquired 3,135 restricted stock units (RSUs) on June 16, 2026.
• The director was also granted 12,555 stock options with an exercise price of $0.7293.
• Both the RSUs and stock options are scheduled to vest on June 16, 2027, contingent upon continued board service.
• Following these transactions, the director holds 8,581 shares directly and maintains an indirect interest in 14,108 shares via ZNZ Holdings LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention of board member through time-based vesting schedules.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Vesting is subject to continued service on the board of directors.
• Market price volatility may impact the future value of the granted options.

Future Outlook

The equity grants are subject to a one-year vesting period, aligning the director's tenure with the company's performance through June 2027.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder interests.

Comparison to Industry Standards

• The use of time-based vesting for director compensation is consistent with standard corporate governance practices for small-cap biotech firms.
• The grant size is typical for non-executive director annual compensation packages.

Related Party Transactions

• Director Rifat Pamukcu serves as Manager Partner of ZNZ Holdings L.L.C., which holds 14,108 shares of the issuer.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on June 16, 2027.

Key Dates

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Compensation, Director Compensation